Fig. 2. Cysteamine protects Cftr^F508del mice from the effects of gliadin in vivo.

a IL-17A, b IFN-γ, and c IL-15 mRNA (left) and protein (right) levels in small intestine homogenates from Cftr^{F508del/F508del} or their Cftr^WT littermates treated with vehicle or cysteamine (60 µg/kg in 100 µl saline/day for 5 days) and then challenged with gliadin for consecutive 4 weeks (5 mg/daily for 1 week and then 5 mg/daily thrice a week for 3 weeks) in the presence or absence of cysteamine (60 µg/kg in 100 µl saline/day) (n = 10 per group). Means ± SD of pooled samples assayed in triplicates. ##p < 0.01 or ### p < 0.001 Cftr^WT versus Cftr^{F508del/F508del}; §p < 0.05 or §§p < 0.01 or §§§p < 0.001 versus cysteamine treatment; **p < 0.01, ***p < 0.001 versus gliadin challenge; °p < 0.05 or °°p < 0.01 or °°°p < 0.001 versus cysteamine + gliadin (ANOVA, Bonferroni post hoc test)